Xbrane Biopharma AB (XBRANE) — Cash Flow-to-Debt Ratio
Xbrane Biopharma AB (XBRANE) has a Cash Flow-to-Debt Ratio of -0.07x as of March 2026, meaning its operating cash flow of Skr-8.50 Million could theoretically repay 0% of its total liabilities (Skr120.60 Million) in one year. Check Xbrane Biopharma AB (XBRANE) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Xbrane Biopharma AB Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Xbrane Biopharma AB across 13 annual periods. Also explore XBRANE total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Xbrane Biopharma AB (2013–2025)
Year-by-year debt coverage analysis for Xbrane Biopharma AB. For market capitalisation and broader financial context, see XBRANE market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.26x | Skr-250.69 Million | Skr110.97 Million | ▼ -970.8% |
| 2024 | -0.21x | Skr-133.73 Million | Skr633.89 Million | ▲ +75.0% |
| 2023 | -0.84x | Skr-406.68 Million | Skr482.17 Million | ▼ -15.5% |
| 2022 | -0.73x | Skr-193.92 Million | Skr265.63 Million | ▲ +14.7% |
| 2021 | -0.86x | Skr-219.61 Million | Skr256.69 Million | ▲ +26.1% |
| 2020 | -1.16x | Skr-238.41 Million | Skr206.06 Million | ▼ -20.4% |
| 2019 | -0.96x | Skr-148.59 Million | Skr154.62 Million | ▼ -449.4% |
| 2018 | 0.28x | Skr46.71 Million | Skr169.81 Million | ▲ +116.8% |
| 2017 | -1.63x | Skr-36.85 Million | Skr22.55 Million | ▲ +55.2% |
| 2016 | -3.65x | Skr-39.43 Million | Skr10.81 Million | ▼ -719.3% |
| 2015 | -0.45x | Skr-12.39 Million | Skr27.82 Million | ▲ +93.5% |
| 2014 | -6.83x | Skr-2.67 Million | Skr390.70K | ▼ -57.1% |
| 2013 | -4.35x | Skr-2.20 Million | Skr505.44K | — |